|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:compatibleWith
|
type 1 diabetes
|
|
gptkbp:contraindication
|
gptkb:medullary_thyroid_carcinoma
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
|
|
gptkbp:discoveredBy
|
late 1990s
|
|
gptkbp:effect
|
weight loss
lower blood glucose
decrease glucagon secretion
increase insulin secretion
reduce HbA1c
reduce appetite
reduce risk of major adverse cardiovascular events
slow gastric emptying
improve glycemic control
cardiovascular benefit
promote satiety
|
|
gptkbp:example
|
gptkb:albiglutide
gptkb:exenatide
gptkb:liraglutide
gptkb:lixisenatide
gptkb:semaglutide
gptkb:dulaglutide
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
GLP-1 agonists
|
|
gptkbp:marketedAs
|
gptkb:Ozempic
gptkb:Rybelsus
gptkb:Victoza
gptkb:Trulicity
gptkb:Byetta
gptkb:Saxenda
gptkb:Tanzeum
gptkb:Adlyxin
|
|
gptkbp:mechanismOfAction
|
GLP-1 receptor activation
|
|
gptkbp:origin
|
synthetic peptide
modified human GLP-1
|
|
gptkbp:prescribes
|
endocrinologists
primary care physicians
|
|
gptkbp:relatedTo
|
gptkb:DPP-4_inhibitors
incretin mimetics
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
oral (semaglutide)
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
pancreatitis
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes
obesity
|
|
gptkbp:bfsParent
|
gptkb:Glucophage
|
|
gptkbp:bfsLayer
|
6
|